



US008697711B2

(12) **United States Patent**
Honigberg et al.

(10) **Patent No.:** **US 8,697,711 B2**
(45) **Date of Patent:** ***Apr. 15, 2014**

(54) **INHIBITORS OF BRUTON'S TYROSINE KINASE**

(56) **References Cited**

U.S. PATENT DOCUMENTS

(75) Inventors: **Lee Honigberg**, San Francisco, CA (US); **Erik Verner**, Belmont, CA (US); **Zhengying Pan**, Austin, TX (US)

(73) Assignee: **Pharmacyclics, Inc.**, Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/479,053**

(22) Filed: **May 23, 2012**

(65) **Prior Publication Data**

US 2012/0252822 A1 Oct. 4, 2012

Related U.S. Application Data

(60) Continuation of application No. 13/472,292, filed on May 15, 2012, which is a continuation of application No. 13/450,158, filed on Apr. 18, 2012, which is a continuation of application No. 13/361,733, filed on Jan. 30, 2012, now Pat. No. 8,399,470, which is a continuation of application No. 13/340,556, filed on Dec. 29, 2011, which is a continuation of application No. 13/340,409, filed on Dec. 29, 2011, which is a continuation of application No. 13/335,719, filed on Dec. 22, 2011, which is a continuation of application No. 13/328,718, filed on Dec. 16, 2011, now Pat. No. 8,476,284, which is a continuation of application No. 13/312,606, filed on Dec. 6, 2011, now Pat. No. 8,497,277, which is a continuation of application No. 13/249,066, filed on Sep. 29, 2011, which is a continuation of application No. 12/356,498, filed on Jan. 20, 2009, now Pat. No. 8,088,781, which is a division of application No. 11/617,645, filed on Dec. 28, 2006, now Pat. No. 7,514,444.

(60) Provisional application No. 60/826,720, filed on Sep. 22, 2006, provisional application No. 60/828,590, filed on Oct. 6, 2006.

(51) **Int. Cl.**
A01N 43/90 (2006.01)
A61K 31/519 (2006.01)
C07D 487/00 (2006.01)

(52) **U.S. Cl.**
USPC **514/262.1; 544/262**

(58) **Field of Classification Search**
None
See application file for complete search history.

5,397,787	A	3/1995	Buzzetti
6,160,010	A	12/2000	Uckun et al.
6,221,900	B1	4/2001	Uckun et al.
6,326,469	B1	12/2001	Ullrich et al.
6,506,769	B2	1/2003	Snow et al.
6,660,744	B1	12/2003	Hirst et al.
6,753,348	B2	6/2004	Uckun et al.
6,770,639	B2	8/2004	Snow et al.
6,921,763	B2	7/2005	Hirst et al.
7,138,420	B2	11/2006	Bentzien et al.
7,332,497	B2	2/2008	Hirst et al.
7,514,444	B2 *	4/2009	Honigberg et al. 514/263.22
7,718,662	B1	5/2010	Chen
7,732,454	B2	6/2010	Verner
7,741,330	B1	6/2010	Chen
7,825,118	B2	11/2010	Honigberg et al.
7,960,396	B2	6/2011	Honigberg et al.
8,008,309	B2	8/2011	Honigberg et al.
8,088,781	B2	1/2012	Honigberg et al.
8,158,786	B2 *	4/2012	Honigberg et al. 544/262
8,232,280	B2 *	7/2012	Honigberg et al. 514/262.1
8,236,812	B2	8/2012	Honigberg et al.
2002/0016460	A1	2/2002	Snow et al.
2002/0155505	A1	10/2002	Wells et al.
2003/0013125	A1	1/2003	Braisted et al.
2003/0040461	A1	2/2003	Mcatee
2003/0125235	A1	7/2003	Foxwell
2004/0006083	A1	1/2004	Hirst et al.
2005/0008640	A1	1/2005	Waegell et al.
2005/0084905	A1	4/2005	Prescott et al.
2005/0090499	A1	4/2005	Currie et al.
2005/0101604	A1	5/2005	Currie et al.
2005/0196851	A1	9/2005	Uckun

(Continued)

FOREIGN PATENT DOCUMENTS

EP	1473039	11/2004
WO	WO-97-28161	8/1997

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 13/869,700, filed Apr. 24, 2013, Buggy et al.

(Continued)

Primary Examiner — Jeffrey Murray

(74) *Attorney, Agent, or Firm* — Wilson, Sonsini, Goodrich & Rosati

(57) **ABSTRACT**

Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

13 Claims, 8 Drawing Sheets